A share price of Sage Therapeutics Inc [SAGE] is currently trading at $8.28, down -4.39%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SAGE shares have gain 2.22% over the last week, with a monthly amount glided 15.16%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, RBC Capital Mkts upgraded its rating to Sector Perform on November 21, 2024, and kept the price target unchanged to $4. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $4 on October 04, 2024. TD Cowen downgraded its rating to a Hold and reduced its price target to $10 on July 30, 2024. JP Morgan downgraded its rating to Neutral for this stock on July 25, 2024, and downed its price target to $12. In a note dated May 29, 2024, Robert W. Baird initiated an Neutral rating and provided a target price of $15 on this stock.
Sage Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $4.62 and $19.34. Currently, Wall Street analysts expect the stock to reach $13.8 within the next 12 months. Sage Therapeutics Inc [NASDAQ: SAGE] shares were valued at $8.28 at the most recent close of the market. An investor can expect a potential return of 66.67% based on the average SAGE price forecast.
Analyzing the SAGE fundamentals
Trailing Twelve Months sales for Sage Therapeutics Inc [NASDAQ:SAGE] were 41.24M which represents -83.56% decline. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -10.47%, Pretax Profit Margin comes in at -9.71%, and Net Profit Margin reading is -9.71%. To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -0.68 and Total Capital is -0.91. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.07 points at the first support level, and at 7.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.65, and for the 2nd resistance point, it is at 9.02.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sage Therapeutics Inc [NASDAQ:SAGE] is 7.42. Also, the Quick Ratio is 7.42, while the Cash Ratio stands at 1.13. Considering the valuation of this stock, the price to sales ratio is 12.34, the price to book ratio is 1.09.
Transactions by insiders
Recent insider trading involved JONAS JEFFREY M, Officer, that happened on Dec 10 ’24 when 7500.0 shares were purchased.
